Novartis’ generic unit Sandoz is now playing a vital role in the research and development (R&D) of biosimilars. The efforts are part of its initiative to compensate for loss of revenue caused by the expiry of patents of blockbuster drugs and providing cost-effective treatments to patients suffering from rare and life-threatening diseases.
By the end of 2016, Sandoz has plans to submit 11 biosimilar molecules for regulatory approval.
